Musculoskeletal
Inflammatory / Fibrotic
Therapeutic Area
15-PGDH INHIBITOR (Oral)
PRECLINICAL
IND ENABLING
PHASE 1
PHASE 2
SarcopeniaPotential label expansion: Sarcopenic obesity
MF-300
Phase 2b
Upcoming Milestones:
✓ Phase 1 completed Q4 ’25
✓ FDA End-of-phase 1 Q1 ’26
- Fast track application Q2 ’26
- Phase 2b FPI Mid ’26
- Phase 2b TLR H2 ’27
Osteoporosis*
MF-300
IND ready
Spinal Muscular Atrophy
MF-300
IND ready
IBD – Ulcerative Colitis, Crohn’s Disease
MF-1305
MF-300
Idiopathic Pulmonary Fibrosis
MF-300